SCHEMBL434274

SCHEMBL434274

COC(=O)c1c(CS(=O)(=O)c2ccccc2)ccc2c1ncc1occc12

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 3/20 0.34
CYP1A2 P05177 3/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
KEAP1 Q14145 5/20 0.33
NFE2L2 Q16236 3/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436372 0.89 TSHR (0.33) KMT2ASMN1; SMN2LMNAPOLBMAPT
SCHEMBL16289869 0.82 ADORA2A (0.32) CYP1A2MAPTKEAP1NFE2L2CYP1A1
SCHEMBL436518 0.75 KCNC1 (0.36) KMT2AMEN1SMN1; SMN2LMNAKDM4E
SCHEMBL1648068 0.71 NCEH1 (0.50) KMT2AMEN1POLBKEAP1NFE2L2
SCHEMBL1648311 0.70 POLB (0.43) KMT2AMEN1POLBKDM4EMAPT
SCHEMBL434137 0.69 POLB (0.35) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL1648347 0.69 METAP2 (0.46) KMT2APOLBMAPTKEAP1NFE2L2
SCHEMBL433290 0.69 POLB (0.35) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL435061 0.68 POLB (0.34) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL438284 0.68 POLB (0.34) KMT2AMEN1SMN1; SMN2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9839623-B2 Tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2017-12-12 US disclosed
US-20160354338-A1 TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-12-08 US disclosed
US-9266896-B2 Tricyclic compounds and methods of making and using same ZAFGEN, INC. (US) 2016-02-23 US disclosed
EP-2595988-B1 TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME ZAFGEN INC (US) 2014-12-17 EP disclosed
EP-2595988-A1 TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME Zafgen, Inc. (US) 2013-05-29 EP disclosed
US-20130123235-A1 Tricyclic Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-05-16 US disclosed
WO-2012012642-A1 TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123235-A1 Tricyclic Compounds and Methods of Making and Using Same CES2, DNPEP, METAP2 SLC40A1 2231/4885KMT2A 916/4885MEN1 1228/4885
US-20160354338-A1 TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME CES2, DNPEP, METAP2 SLC40A1 2231/4885KMT2A 916/4885MEN1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.